CP 060S

Drug Profile

CP 060S

Latest Information Update: 08 Nov 2006

Price : $50

At a glance

  • Originator Chugai Pharmaceutical
  • Class Anti-ischaemics; Antiarrhythmics
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arrhythmias; Ischaemic heart disorders

Most Recent Events

  • 08 Nov 2006 Discontinued - Preclinical for Ischaemic heart disorders in Japan (unspecified route)
  • 08 Nov 2006 Discontinued - Preclinical for Arrhythmias in Japan (unspecified route)
  • 09 Nov 1999 Two studies have been added to the Ischaemic Heart Disease pharmacodynamics section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top